Amphastar Pharmaceuticals Files 8-K

TL;DR

AMPH filed an 8-K for financial updates, nothing major disclosed yet.

AI Summary

On May 8, 2024, Amphastar Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or new material events were detailed in the provided excerpt.

Why It Matters

This filing indicates Amphastar Pharmaceuticals is providing updates on its financial performance and condition to the SEC, which is standard practice for public companies.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for financial reporting and does not disclose any new risks or material adverse events.

Key Players & Entities

• Amphastar Pharmaceuticals, Inc. (company) — Filer of the 8-K report
• May 8, 2024 (date) — Date of the report
• 11570 Sixth Street, Rancho Cucamonga, California 91730 (address) — Principal executive offices
• 909-980-9484 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share AMPH The NASDAQ Stock Mar

Filing Documents

• amph-20240508x8k.htm (8-K) — 105KB
• amph-20240508xex99d1.htm (EX-99.1) — 466KB
• 0001297184-24-000033.txt ( ) — 716KB
• amph-20240508.xsd (EX-101.SCH) — 3KB
• amph-20240508_lab.xml (EX-101.LAB) — 15KB
• amph-20240508_pre.xml (EX-101.PRE) — 10KB
• amph-20240508x8k_htm.xml (XML) — 5KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On May 8, 2024, Amphastar Pharmaceuticals, Inc. issued a press release announcing its financial results for the three months ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) E xhibits: Exhibit No. Description 99.1 P r e ss r e l ea s e, d a t e d May 8, 2024 , issu e d by Amphastar Pharmaceuticals, I nc . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE P ursu a nt to the r e quir e m e nts of the Securities Exchange Act of 1934, the r e gistr a nt h a s duly caused this r e port to b e sign e d on its b e h a lf by the und e rsign e d h e r e unto duly a uthori ze d . Da t e : May 8, 2024 Amphastar Pharmaceuticals, I nc . By: / s/ WILLIAM J. PETERS W illi am J . Peters C hi e f F in a nci a l O ffic e r, Executive Vice President a nd Treasurer